Live feed08:00:00·630dPRReleasevia QuantisnowFirst Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerByQuantisnow·Wall Street's wire, on your screen.URGN· UroGen Pharma Ltd.Health Care
